Second-line outcomes in metastatic colorectal cancer – raising the bar for the high jump rather than the doing the limbo

References

• GLOBOCAN. Estimated colorectal cancer mortality worldwide in 2012. (International Agency for Research on Cancer (IARC). 2012
   Google Scholar
• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64(2):104-17
   PubMed Web of Science ®Google Scholar
• Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med 2010;170(6):537-42
   PubMedGoogle Scholar
• Alan P, Venook DN, Heinz-Josef L, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014;32(Suppl 5s):abstr LBA3
   Google Scholar
• Kriza C, Emmert M, Wahlster P, et al. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics 2013;31(7):577-88
   PubMed Web of Science ®Google Scholar
• Zafar SY, Marcello JE, Wheeler JL, et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009;5(5):228-33
   PubMedGoogle Scholar
• Hess GP, Wang PF, Quach D, et al. Systemic Therapy for Metastatic Colorectal Cancer: patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice. J Oncol Pract 2010;6(6):301-7
   PubMedGoogle Scholar
• Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17(12):1486-95
   PubMed Web of Science ®Google Scholar
• Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32(12):1277-80
   PubMed Web of Science ®Google Scholar
• EMA. Guideline on the evaluation of anticancer medicinal products in man. European Medicines Agency EMA/CHMP/205/95/rev.4 2011
   Google Scholar
• Beishon M. Approval rating: how do the EMA and FDA compare? Cancer World 2014;12-17
   Google Scholar
• Hartmann M, Mayer-Nicolai C, Pfaff O. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union. Crit Rev Oncol Hematol 2013;87(2):112-21
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2008;26(14):2311-19
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905-14
   PubMed Web of Science ®Google Scholar
• Hay JL, Atkinson TM, Reeve BB, et al. Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res 2014;23(1):257-69
   PubMed Web of Science ®Google Scholar
• ASCO. Value in Cancer Care Task Force. Available from: www.asco.org/advocacy/asco-action-brief-value-cancer-care. 2014
   Google Scholar
• Cost-effectiveness analysis registry. Available from: https://research.tufts-nemc.org/cear4/SearchingtheCEARegistry/SearchtheCEARegistry.aspx
   Google Scholar
• Haug U, Engel S, Verheyen F, Linder R. Estimating colorectal cancer treatment costs: a pragmatic approach exemplified by health insurance data from Germany. PLoS ONE 2014;9(2):e88407
   Web of Science ®Google Scholar
• de Oliveira C, Bremner KE, Pataky R, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open 2013;1(1):E1-8
   Google Scholar
• Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the united states: 2000-2020. J Natl Cancer Ins 2008;100(24):1763-70
   PubMedGoogle Scholar
• Hanly PA, Sharp L. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer 2014;14(1):224
   PubMedGoogle Scholar
• Tilson L, Sharp L, Usher C, et al. Cost of care for colorectal cancer in Ireland: a health care payer perspective. Eur J Health Econ 2012;13(4):511-24
   PubMed Web of Science ®Google Scholar
• Leung HW, Chan AL, Leung MS, Lu CL. Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer. Annals of Pharmacotherapy 2013;47(4):506-18
   PubMed Web of Science ®Google Scholar
• Wong YN, Meropol NJ, Speier W, et al. Cost implications of new treatments for advanced colorectal cancer. Cancer 2009;115(10):2081-91
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3):374-9
   PubMed Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19(3):508-15
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
   PubMed Web of Science ®Google Scholar
• Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of canada clinical trials group co.17 Trial. J Natl Cancer Inst 2009;101(17):1182-92
   PubMedGoogle Scholar
• Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413-18
   PubMed Web of Science ®Google Scholar
• Hoyle M, Crathorne L, Peters J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess 2013;17(14):1-237
   PubMed Web of Science ®Google Scholar
• Hoyle M, Peters J, Crathorne L, et al. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for kras wild-type patients with metastatic colorectal cancer. Value Health 2013;16(2):288-96
   PubMed Web of Science ®Google Scholar
• NICE. Available from: www.nice.org.uk/
   Google Scholar
• UICC. Background to the World Cancer Declaration 2013. Union for International Cancer Control, (2013 )
   Google Scholar
• Lawler M, Le Chevalier T, Murphy MJJr, et al. A catalyst for change: the European cancer Patient’s Bill of Rights. Oncologist 2014;19(3):217-24
   PubMed Web of Science ®Google Scholar
• Peppercorn J, Zafar SY, Houck K, et al. Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol 2014;15(3):e132-8
   Web of Science ®Google Scholar
• Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8(5):521-33
   PubMed Web of Science ®Google Scholar
• Doble B, Harris A, Thomas DM, et al. Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics 2013;14(12):1405-17
   PubMed Web of Science ®Google Scholar
• Moldrup C. No cure, no pay. BMJ 2005;330(7502):1262-4
   PubMed Web of Science ®Google Scholar
• Porter ME. What is value in health care? N Engl J Med 2010;363(26):2477-81
   PubMed Web of Science ®Google Scholar
• FDA. Available from: www.accessdata.fda.gov
   Google Scholar